Clinical Trial Update: Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of dasatinib in Chronic myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: European Society for Blood and Marrow Transplantation | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: TERMINATED